Although SGLT2 inhibitors do not reduce the risk of ischemic stroke incidence, they affect the most important cerebrovascular risk factors, including hyperglycemia, hypertension, obesity, dyslipidemia, and atherosclerosis [112]. This evidence concerns the gene SLC5A2 and atherosclerosis.